9,10-二去氢-N-乙基-6-甲基麦角灵-8b-甲酰胺 | 478-99-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 麦角林及其衍生物
• 中文名称: 9,10-二去氢-N-乙基-6-甲基麦角灵-8b-甲酰胺
• 英文名称: lysergic acid ethylamide
• 英文别名: Deethyl-LSD；6-methyl-9,10-didehydro-ergoline-8-carboxylic acid ethylamide；(6aR,9R)-N-ethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
• CAS: 478-99-9
• 化学式: C₁₈H₂₁N₃O
• 分子量: 295.384
• InChiKey: VEBWTGYUIBTVNR-MLGOLLRUSA-N

物化性质

• 熔点：
  153-155 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  437.06°C (rough estimate)
• 密度：
  1.1190 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  48.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  麦角乙二胺 以 甲醇 为溶剂， 以1%的产率得到Lysergic acid ethylvinylamide
  参考文献：
  名称：

  Ishii, Hisashi; Niwaguchi, Tetsukichi; Nakahara, Yuji, Journal of the Chemical Society. Perkin transactions I, 1980, p. 902 - 905

  摘要：

  DOI：

文献信息

• INDUCED MALIGNANT STEM CELLS
  申请人：National Cancer Center

  公开号：US20140137274A1

  公开（公告）日：2014-05-15

  PROBLEM There are provided induced malignant stem cells capable of in vitro proliferation that are useful in cancer research and drug discovery for cancer therapy, as well as processes for production thereof, cancer cells derived from these cells, and applications of these cells. MEANS FOR SOLVING An induced malignant stem cell capable of in vitro proliferation are characterized by satisfying the following two requirements: (1) having at least one aberration selected from among (a) an aberration of methylation (high or low degree of methylation) in a tumor suppressor gene or a cancer-related genetic region in endogenous genomic DNA, (b) a somatic mutation of a tumor suppressor gene or a somatic mutation of an endogenous cancer-related gene in endogenous genomic DNA, (c) abnormal expression (increased or reduced/lost expression) of an endogenous oncogene or an endogenous tumor suppressor gene, (d) abnormal expression (increased or reduced/lost expression) of a noncoding RNA such as an endogenous cancer-related microRNA, (e) abnormal expression of an endogenous cancer-related protein, (f) an aberration of endogenous cancer-related metabolism (hypermetabolism or hypometabolism), (g) an aberration of endogenous cancer-related sugar chain, (h) an aberration of copy number variations in endogenous genomic DNA, and (i) instability of microsatellites in endogenous genomic DNA in an induced malignant stem cell; and (2) expressing genes including POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

  问题：提供了一种在体外增殖的诱导恶性干细胞，可用于癌症研究和癌症治疗药物发现，以及其生产过程，从这些细胞衍生的癌细胞和这些细胞的应用。 解决方法：一种在体外增殖的诱导恶性干细胞，其特征在于满足以下两个要求： （1）具有来自内源基因组DNA中肿瘤抑制基因或癌症相关遗传区的甲基化异常（高度或低度甲基化），内源基因组DNA中肿瘤抑制基因的体细胞突变或内源性癌症相关基因的体细胞突变，内源性癌基因或内源性肿瘤抑制基因的异常表达（增加或减少/丢失表达），内源性癌症相关microRNA等非编码RNA的异常表达，内源性癌症相关蛋白质的异常表达，内源性癌症相关代谢异常（高代谢或低代谢），内源性癌症相关糖链的异常，内源基因组DNA中拷贝数变异的异常，以及诱导恶性干细胞中微卫星的不稳定性；以及 （2）表达包括POU5F1基因、NANOG基因、SOX2基因和ZFP42基因在内的基因。
• INDUCED HEPATIC STEM CELL AND PROCESS FOR PRODUCTION THEREOF, AND APPLICATIONS OF THE CELL
  申请人：National Cancer Center Research Institute

  公开号：EP2532741A1

  公开（公告）日：2012-12-12

  The present invention relates to an induced hepatic stem cell defined as follows, a process for production thereof, and applications of the cell, which are useful in safety tests, toxicity tests, metabolism tests, drug interaction tests, antiviral activity tests, screening tests for pharmaceuticals such as hyperlipidemic therapeutics, hypertension therapeutics, low-molecular weight compound medicaments, and antibody medicaments, screening for targets in drug discovery, preparation of animal models, production of hepatocyte-produced proteins, and in regenerative medicine. The induced hepatic stem cell of the present invention is characterized by at least satisfying the following requirements (1)-(3): (1) it expresses at least 15 genes as selected from the group of the genes which are marker genes for an embryonic stem cell; (2) it has properties of a hepatocyte; and (3) it can be subjected to expansion culture or passage culture for at least 3 days.

  本发明涉及一种定义如下的诱导肝干细胞、其生产工艺以及该细胞的应用，该细胞可用于安全性试验、毒性试验、代谢试验、药物相互作用试验、抗病毒活性试验、高血脂治疗药物、高血压治疗药物、低分子量化合物药物和抗体药物等药物的筛选试验、药物发现中靶点的筛选、动物模型的制备、肝细胞生产蛋白的生产以及再生医学中。本发明的诱导肝干细胞的特征是至少满足以下要求（1）-（3）：（1）表达至少 15 个基因，这些基因选自胚胎干细胞标记基因组；（2）具有肝细胞的特性；（3）可进行至少 3 天的扩增培养或传代培养。
• INDUCED MALIGNANT STEM CELLS OR PRE-INDUCTION CANCER STEM CELLS CAPABLE OF SELF-REPLICATION OUTSIDE OF AN ORGANISM, PRODUCTION METHOD FOR SAME, AND PRACTICAL APPLICATION FOR SAME
  申请人：National Cancer Center

  公开号：EP2599860A1

  公开（公告）日：2013-06-05

  The present invention provides an induced cancer cell capable of self-replication in vitro which is useful in cancer therapy research and the research for cancer-related drug discovery, processes for production thereof, cancer cells induced by the malignant cells, and applications of these cells. The present invention provides an induced cancer stem cell capable of proliferation (self-replication) in vitro, wherein the induced cancer stem cell has the following two characteristics: (1) expressing the six genes (self-renewal related genes) POU5F1, NANOG, SOX2, ZFP42, LIN28, and TERT selected from a certain group of genes; and (2) having an aberration which is either (a) a mutation in an endogenous tumor suppressor gene or (b) increased expression of an endogenous cancer-related gene.

  本发明提供了一种能在体外自我复制的诱导癌细胞，它可用于癌症治疗研究和癌症相关药物的发现研究、其生产工艺、恶性细胞诱导的癌细胞以及这些细胞的应用。 本发明提供了一种能够在体外增殖（自我复制）的诱导癌症干细胞，其中诱导癌症干细胞具有以下两个特征： (1) 表达选自某组基因的六个基因（自我更新相关基因）POU5F1、NANOG、SOX2、ZFP42、LIN28 和 TERT；以及 (2) 具有畸变，即(a)内源性肿瘤抑制基因突变或(b)内源性癌症相关基因表达增加。
• METHOD FOR PREPARING HUMAN HEPATOCYTE PROGENITOR CELLS
  申请人：National Cancer Center

  公开号：EP3533865A1

  公开（公告）日：2019-09-04

  Provided is a method for reprogramming human mature hepatocytes in vitro into liver progenitor cells capable of self-renewal. Disclosed is a method for preparing human liver progenitor cells, comprising culturing human mature hepatocytes in a medium containing serum, A-83-01, and CHIR99021.

  本发明提供了一种在体外将人类成熟肝细胞重编程为能够自我更新的肝祖细胞的方法。本发明公开了一种制备人肝祖细胞的方法，包括在含有血清、A-83-01 和 CHIR99021 的培养基中培养人成熟肝细胞。
• A METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS
  申请人：INSERM - Institut National de la Santé et de la Recherche Médicale

  公开号：EP2451836A1

  公开（公告）日：2012-05-16